June 12, 2025 08:22 PM EDTUpdated 08:00 AM
Pharma
FDA+

Mod­er­na wins ex­pand­ed la­bel for RSV shot, al­low­ing use in at-risk, younger adults

Max Bayer

Pharma Reporter

A lit­tle more than a week af­ter Mod­er­na’s new Covid-19 vac­cine was ap­proved, the FDA has ex­pand­ed who can re­ceive the com­pa­ny’s RSV shot. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times